Skip to main content

Advertisement

Table 1 Baseline characteristics of the 31 participants at the pre-infection visit

From: A prospective study of vaginal trichomoniasis and HIV-1 shedding in women on antiretroviral therapy

Characteristic Median (IQR) or Number (percent)
Demographics  
   Age (years) 36 (31 - 38)
   Education (years) 7 (7 - 8)
Pregnant 1 (3.2)
Hormonal contraceptive method 7 (22.6)
   OCP 1 (3.2)
   DMPA 4 (12.9)
   Norplant 2 (6.5)
Risk Behavior  
   Number of partners in the last week 0 (0 - 1)
   Frequency of intercourse in the last week 0 (0 - 2)
   Percent condom use in the last weeka 100 (75 - 100)
Clinical  
   WHO HIV staging at ART initiation  
Stage I 3 (9.7)
Stage II 8 (25.8)
Stage III 17 (54.8)
Stage IV 3 (9.7)
CD4 lymphocyte count (cells/ml)  
   At start of antiretroviral therapy 126 (68 - 159)
   Pre-infection visitb 241 (161 - 292)
On stavudine, lamivudine, and nevirapinec 30 (96.7)
Time since ART initiation (months) 10.3 (3.6 - 19.0)
ART adherence in the past month  
   On-time refillsd 27 (87.1)
   Pill count adherence ≥ 95% 21 (67.7)
  1. IQR, interquartile range.
  2. a Among 15 women who reported sexual intercourse in the last week.
  3. b CD4 count at the pre-infection visit or nearest visit prior to infection was used.
  4. c One woman was on a second-line regimen consisting of lopinavir/ritonavir, didanosine, and zidovudine.
  5. d Late refills were defined as occurring > 48 hours after a refill was due.